Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Tuesday, 9 July 2013
- AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research AstraZeneca today announced that it has entered into an agreement with the University of Cambridge
- Friday, 28 June 2013
- AstraZeneca Completes Acquisition Of Pearl Therapeutics AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics
- Monday, 17 June 2013
- MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones